Development pipeline

Fibrinogen (BT-524)

BT-524 is a human fibrinogen concentrate purified from human plasma.

Fibrinogen is a plasma protein produced by the liver, which is an important component of blood clotting. A deficiency of autologous fibrinogen means that the blood’s ability to clot is impaired, which leads to a greatly increased risk of bleeding and additionally to a delay in bleeding cessation.

In the case of congenital fibrinogen deficiency patients can not produce sufficient or any fibrinogen. In acquired fibrinogen deficiency, on the other hand, patients lose fibrinogen because of heavy bleeding, for example due to severe injuries and surgery. In both cases, fibrinogen must be supplied again to stop bleeding.

The fibrinogen (BT-524) developed by Biotest is currently being investigated clinically in a multinational phase I/III trial in patients with congenital fibrinogen deficiency.

Press releases

Biotest takes over Cara Plasma s.r.o. with one plasma c...

19.07.2017, News

Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic - Long-term plasma supplier Cara Plasma was taken over by Biotest - Biotest has now 16 plasma ... [More]

Biotest reaches 2nd milestone in Biotest Next Level exp...

22.06.2017, News

Biotest reaches 2nd milestone in Biotest Next Level expansion project - Authorities grant building approval - Relocation activities of laboratories and offices for production start in June ... [More]

Biotest AG shareholders accept voluntary public tender ...

14.06.2017, News

Biotest AG shareholders accept voluntary public tender offer by CREAT Group Dreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the voluntary public tender offer by Tiancheng ... [More]

Release according to Article 26, Section 1 of the WpHG ...

12.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of shares ... [More]

Biotest sold US therapy business to ADMA Biologics, Inc...

07.06.2017, News

Biotest sold US therapy business to ADMA Biologics, Inc. - Biotest receives 50% minus one share of ADMA - Biotest receives also distribution rights of specified current product and a right of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

06.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

01.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

01.06.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Joint reasoned statement of Biotest AG - Management Boa...

01.06.2017, News

Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group Dreieich, 1 June, 2017. Today, the Management Board and Supervisory ... [More]

Release according to Article 26, Section 1 of the WpHG ...

24.05.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Publication of the offer document on the voluntary publ...

18.05.2017, News

Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group - Offer document reaffirms the offer announced on April 7, 2017 - The Management Board and the ... [More]

DGAP-AFR: Biotest AG: Preliminary announcement of the p...

17.05.2017, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Financial report (half-year/Q2) Date of disclosure / German: August 14, 2017 Date of disclosure / ... [More]

Biotest AG opens seventh plasma collection centre in Hu...

16.05.2017, News

Biotest AG opens seventh plasma collection centre in Hungary - 15 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 16 May 2017. Biotest ... [More]

Biotest reports revenue of EUR 110 million in the first...

10.05.2017, News

Biotest reports revenues of EUR 110.5 million in the first quarter 2017 Dreieich, 10 May 2017. In the first quarter of 2017, the Biotest Group generated sales of EUR 110.5 million, after EUR 133.6 ... [More]

Correction of a release from 07.04.2017, 15:23 CET/CEST...

04.05.2017, PVR

Correction of a notification of Major Holding published on 07.04.2017 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for ... [More]

Release according to Article 26, Section 1 of the WpHG ...

28.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Voluntary recall of human albumin

26.04.2017, News

Biotest: Voluntary recall of human albumin - Already quarantined batches of human albumin are recalled - Consequences of the one-time effect on Sales and EBIT are currently being evaluated - As ... [More]

Biotest recalls human albumin and reduces forecast

26.04.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest recalls human albumin and reduces forecast Dreieich, 26 April 2017. In close co-operation with regulatory ... [More]

Biotest AG opens sixth plasma collection centre in Hung...

19.04.2017, News

Biotest AG opens sixth plasma collection centre in Hungary - 14 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 19 April 2017. Biotest ... [More]

Biotest informs about limited availability of albumin

13.04.2017, News

Biotest informs about limited availability of albumin - Due to an equipment failure the availability of albumin is currently limited - Consequences on sales and annual results are currently not ... [More]

Clinical trials

Title

Indication

Status

 
Fibrinogen (Study 984) Congenital fibrinogen deficiency Study ongoing

A prospective, open-label, uncontrolled, single dose phase I/III study investigating pharmacokinetic properties, efficacy, safety, and tolerability of BT524 (fibrinogen concentrate from human plasma) in patients with congenital fibrinogen deficiency

Link clinicaltrials.gov